NASDAQ:COAG Hemab Therapeutics Q1 2026 Earnings Results & Report $31.62 +0.73 (+2.36%) As of 10/9/2026 04:00 PM Eastern Hemab Therapeutics reported Q1 2026 earnings on May 21, 2026. The company reported EPS of -$23.98. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 21, 2026TimeBefore Market OpensConference Call7:00 AM ET Hemab Therapeutics EPS ResultsActual EPS-$23.98Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AHemab Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Hemab Therapeutics Q1 2026 Earnings FAQ Did Hemab Therapeutics beat earnings estimates for Q1 2026? Hemab Therapeutics (NASDAQ:COAG) reported earnings of -$23.98 per share for Q1 2026. The report was announced on Thursday, May 21, 2026. Hemab Therapeutics Earnings HeadlinesHemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Stock Has Consensus Target Price of $51.40October 1, 2026 | americanbankingnews.comHemab Therapeutics: The Market Is Pricing One Rung Of A Four-Rung LadderSeptember 29, 2026 | seekingalpha.comNo. 1 stock to cash in on the death of iPhoneAnalyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.October 10 at 1:00 AM | Stansberry Research (Ad)Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount?September 29, 2026 | finance.yahoo.comHemab Therapeutics Holdings, Inc. Announces Board and Committee Changes, Effective September 24, 2026September 25, 2026 | marketscreener.comMHemab Therapeutics Strengthens Board of Directors with Appointment of Keli WalbertSeptember 24, 2026 | globenewswire.comSee More Hemab Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hemab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemab Therapeutics and other key companies, straight to your email. Email Address About Hemab TherapeuticsHemab Therapeutics (NASDAQ:COAG) (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients. Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor. The program is being developed initially for Glanzmann thrombasthenia, a rare inherited platelet disorder, with potential applications in other bleeding conditions. Hemab conducts its operations in the United States and Denmark and is advancing its pipeline through clinical development and related research. As a development-stage biotechnology company, its products remain investigational and subject to clinical and regulatory review.View Hemab Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
